Established in 1999, the BIONET Group has leveraged cross-border technologies to drive transformative changes in shaping our future as a leading innovator in the fields of cell therapy, precision health, and digital healthcare. The BIONET Group is composed of three subsidiary companies, BIONET Corp., GGA Corp. and BIONET Therapeutics Corp. The BIONET Therapeutics Corp. is dedicated to accelerate the development of various regenerative medicine treatments and new applications of cell therapy.
Our cutting-edge products and technologies, including stem cells, exosomes, genetic testing, CDMO and skin care products, have benefited over 1.6 million people across 17 countries. We serve over 50% of newborns and 95.5% of reproductive medicine centers in Taiwan, and has collaborated with over 500 medical institutions worldwide. Committed to pushing the boundaries of regenerative medicine, precision health, and digital healthcare, the BIONET Group strives to lead the industry and enhance the quality of life for people around the world.